Head-To-Head Comparison: Whitehawk Therapeutics (NASDAQ:WHWK) vs. IMV (OTCMKTS:IMVIQ)

Whitehawk Therapeutics (NASDAQ:WHWK) and IMV (OTCMKTS:IMVIQ) are both small-cap manufacturing companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk.

Risk and Volatility

Whitehawk Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, IMV has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

Profitability

This table compares Whitehawk Therapeutics and IMV’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-68.32%	-63.21%
IMV	N/A	N/A	N/A

Valuation and Earnings

This table compares Whitehawk Therapeutics and IMV”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$25.98 million	6.37	-$63.69 million	$0.14	25.07
IMV	$330,000.00	0.00	-$37.99 million	($4.59)	N/A

IMV has lower revenue, but higher earnings than Whitehawk Therapeutics. IMV is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 0.3% of IMV shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Whitehawk Therapeutics and IMV, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1	1	2	0	2.25
IMV	0	0	0	0	0.00

Whitehawk Therapeutics currently has a consensus price target of $6.50, suggesting a potential upside of 85.19%. Given Whitehawk Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Whitehawk Therapeutics is more favorable than IMV.

Summary

Whitehawk Therapeutics beats IMV on 7 of the 11 factors compared between the two stocks.

About Whitehawk Therapeutics

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

About IMV

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.